Guru Fundamental Report for HIMS

Validea's guru fundamental report rates HIMS & HERS HEALTH INC (HIMS), a large-cap biotechnology firm, at 75% using its Small-Cap Growth Investor model, based on Motley Fool's strategy. While HIMS passed numerous fundamental criteria including profit margin, relative strength, and cash flow from operations, it notably failed on key financial and valuation metrics such as cash and cash equivalents, sales, and the P/E to growth ratio. This 75% score places HIMS below the 80% threshold typically indicating 'some interest' for this growth-oriented strategy, suggesting it does not fully align with the model's investment criteria despite some strong fundamentals.

Analysis

Hims & Hers Health Inc. (HIMS) scores 75% on Validea's Small-Cap Growth Investor model, a rating that falls below the 80% threshold typically required to indicate strategic interest. The analysis reveals a company with strong operational fundamentals and favorable growth characteristics, passing crucial tests for profit margin, profit margin consistency, cash flow from operations, and relative price strength. Furthermore, HIMS demonstrates positive insider holdings and effective management of inventory and accounts receivable relative to sales. However, these strengths are counterbalanced by significant weaknesses, including failures on key metrics for cash and cash equivalents, average shares outstanding, and daily dollar volume. Critically, the company fails the 'Fool Ratio' test, indicating its price-to-earnings multiple may be high relative to its growth rate. The report also presents a mixed signal on revenue, passing on year-over-year sales growth but failing on an absolute sales benchmark, suggesting that while the growth trajectory is strong, its scale may not yet meet the model's criteria.

Key Decisions for Investors

• Investors should view HIMS as a growth company with notable red flags; while operational performance is strong, the stock's valuation appears stretched according to this model's P/E-to-growth metric.
• A deeper due diligence on the balance sheet is warranted, specifically concerning the weak cash and cash equivalents position, before initiating or adding to a position.
• Given the sub-80% score, growth-oriented investors might consider HIMS a 'hold' or place it on a watchlist, pending improvements in its valuation and key financial health indicators like its cash position.